|
Market Closed -
OTC Markets
21:20:45 07/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.7500 USD | +2.88% |
|
0.00% | -71.15% |
| 10-15 | 14 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange | FW |
| 10-14 | Orexo reports promising results for oral semaglutide tablet | FW |
| Market Cap | 213M 21.49M 19.16M 17.75M 16.13M 30.28M 2.04B 30.77M 83.69M 1.06B 80.63M 78.94M 3.4B | P/E 2024 |
-2.97x | P/E 2025 | 1.63x |
|---|---|---|---|---|---|
| Enterprise Value | -208M -21.01M -18.73M -17.35M -15.77M -29.6M -1.99B -30.08M -81.82M -1.04B -78.82M -77.17M -3.33B | EV / Sales 2024 |
1.62x | EV / Sales 2025 | 23.8x |
| Free-Float |
78.37% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Orexo AB
| 1 day | +2.88% | ||
| Current month | -31.82% | ||
| 1 month | -46.04% | ||
| 3 months | -58.33% | ||
| 6 months | -71.70% | ||
| Current year | -71.15% |
| 1 month | 0.73 |  | 1.26 |
| Current year | 0.73 | | 2.65 |
| 1 year | 0.73 | | 3 |
| 3 years | 0.73 | | 4.05 |
| 5 years | 0.73 | | 4.05 |
| 10 years | 0.73 | | 9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 54 | 05/02/2013 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 59 | 01/09/2022 |
Jonas Savmarker
CTO | Chief Tech/Sci/R&D Officer | - | 01/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 01/01/2002 | |
George Wilkinson
BRD | Director/Board Member | 70 | 11/04/2019 |
Christine Rankin
BRD | Director/Board Member | 62 | 01/04/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.88% | 0.00% | - | - | 22.16M | |
| -1.33% | +4.88% | +54.50% | +109.94% | 1,120B | |
| -0.69% | -3.77% | +31.35% | +66.62% | 616B | |
| -0.96% | +0.55% | +23.13% | +94.26% | 504B | |
| +0.24% | +5.58% | +33.98% | +59.40% | 367B | |
| -1.59% | -1.25% | +69.39% | +43.02% | 360B | |
| -0.40% | +3.53% | +19.17% | +46.55% | 288B | |
| -0.37% | +3.11% | -1.26% | +18.23% | 258B | |
| -1.75% | +1.76% | +42.21% | +51.44% | 234B | |
| -2.00% | +1.75% | +24.64% | +95.14% | 194B | |
| Average | -0.60% | +2.30% | +33.01% | +64.95% | 437.88B | |
| Weighted average by Cap. | -0.99% | +2.42% | +37.90% | +75.52% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 590M 59.57M 53.1M 49.19M 44.73M 83.93M 5.65B 85.31M 232M 2.95B 224M 219M 9.44B | 26M 2.63M 2.34M 2.17M 1.97M 3.7M 249M 3.76M 10.22M 130M 9.85M 9.64M 416M |
| Net income | -203M -20.5M -18.27M -16.92M -15.39M -28.88M -1.94B -29.35M -79.83M -1.02B -76.9M -75.29M -3.25B | 639M 64.55M 57.54M 53.3M 48.46M 90.94M 6.12B 92.43M 251M 3.2B 242M 237M 10.22B |
| Net Debt | 353M 35.61M 31.74M 29.41M 26.74M 50.17M 3.38B 51M 139M 1.76B 134M 131M 5.64B | -421M -42.5M -37.88M -35.09M -31.91M -59.87M -4.03B -60.86M -166M -2.11B -159M -156M -6.73B |
Employees
61
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/10/26 | $0.000000 | - | 8 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ORX Stock
- ORXO.Y Stock
Select your edition
All financial news and data tailored to specific country editions
